Global Cancer Spit Test Market, By Cancer Type (Bladder Cancer, Breast Cancer, Colon and Rectal Cancer, Endometrial Cancer, Kidney Cancer, Leukemia, Liver-Lung Cancer, Melanoma, Non-Hodgkin Lymphoma, Pancreatic Cancer, Prostate Cancer, Thyroid Cancer), End-use (Hospitals, Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes), Site of Collection (Parotid Gland, Submandibular/Sublingual Gland, Minor Salivary Glands) – Industry Trends and Forecast to 2029.
Cancer Spit Test Market Analysis and Size
The market for cancer spit test is expected to grow during the forecast period. The factors such as the rising number of patients with various types of cancer around the world, the expansion of diagnostic facilities in developing nations, and technological advancements will all contribute to the market for cancer spit test. North America dominates the cancer spit test market due to the adoption of advanced technology along with rising number of laboratories in the region.
Data Bridge Market Research analyses that the global cancer spit test market which is expected to undergo a CAGR of 10% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Cancer Spit Test Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Cancer Type (Bladder Cancer, Breast Cancer, Colon and Rectal Cancer, Endometrial Cancer, Kidney Cancer, Leukemia, Liver-Lung Cancer, Melanoma, Non-Hodgkin Lymphoma, Pancreatic Cancer, Prostate Cancer, Thyroid Cancer), End-use (Hospitals , Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes), Site of Collection (Parotid Gland, Submandibular/Sublingual Gland, Minor Salivary Glands)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Thermo Fisher Scientific Inc. (U.S.), BD (U.S.), Bio-Rad Laboratories, Inc. (U.S.), bioMérieux (France), Merck KGaA (Germany), RayBiotech Life Inc. (U.S.), R&D Systems, Inc. (U.S.), AESKU.GROUP GmbH & Co. KG (Germany), Eurofins Scientific (Luxembourg), Biogenuix (India), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.), Danaher (U.S.), Sysmex Corporation (Japan), PerkinElmer Inc. (U.S.), Agilent Technologies Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
A spit test could detect head and neck malignancies early. Even prior to the onset of symptoms, tumour DNA can be found in blood plasma and saliva. Through sarah schwartz saliva testing may enable doctors to identify head and neck malignancies earlier. The second most prevalent cause of mortality among people in the world is cancer. There is an urgent need for the development of quick, extremely accurate, and non-invasive methods for cancer screening, early detection, treatment, staging, and prognostics.
Global Cancer Spit Test Market Dynamics
Drivers
- Rise in cases of cancer
In the forecast period of 2022–2029, factors such as the rising number of patients with various types of cancer around the world, the rise in government initiatives aimed at cancer prevention, the expansion of diagnostic facilities in developing nations, and technological advancements will all contribute to the market for cancer spit test growing more quickly than expected.
- Acceptance of non-invasive saliva testing
The market for cancer spit tests will rise during the forecast period due to a number of factors, including the acceptance of non-invasive saliva testing over blood draws.
Opportunities
The cancer spit test growth is fuelled by an increase in the number of research and development activities. This will provide beneficial opportunities for the cancer spit test growth.
Moreover, increase in the number of emerging markets and new product launches will further provide beneficial opportunities for the cancer spit test market growth during the forecast period.
Restraints/Challenges
On the other hand, growing number of misconceptions along with poor network of laboratories will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the market.
This global cancer spit test market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global cancer spit test market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Cancer Spit Test Market
According to data from the World Bank, the COVID-19 pandemic has caused a reduction in the global GDP of around 3.5 percent in 2020. As 2021 approaches, many nations' economies have begun to recover and partially adapted to pandemic limitations. The development of vaccines has advanced significantly, and numerous governments have also implemented a variety of policies to boost economic recovery. These initiatives, particularly in the United States, are likely to boost the economy significantly, but the outlook for sustainable growth varies greatly between nations and industries. Although the world economy is emerging from the COVID-19-induced downturn, it will lag behind pre-pandemic trends for a considerable amount of time. The hazards connected with the decade-long surge of increased global debt have been made worse by the pandemic.
Recent Development
- In April 2021, Molecular diagnostics platform Idylla from Biocartis, which is quick and simple to use, will be used to build the innovative proprietary test called the Merlin Assay from SkylineDx. This relationship was announced by the two companies. This test aims to forecast a patient's likelihood of nodal melanoma metastases. This alliance helped the business generate revenue and improved its reputation in the marketplace.
- In February 2021, Thermo Fisher Scientific received six CMO Leadership Awards. Including capabilities, compatibility, knowledge, quality, reliability, and service, it triumphed in all six areas. Thermo Fisher has now been acknowledged in each of the six categories for the second year running, making this the company's ninth overall CMO Leadership Awards accolade. This has helped the business generate more income and boosted its credibility.
- In January 2021, The OrageneDx product family was given a general use 510(k) approval by the U.S. Food and Drug Administration (FDA), according to a statement released by DNA Genotek. The company's market credibility has improved as a result of this FDA approval, which has also enhanced sales of this product.
Global Cancer Spit Test Market Scope
The global cancer spit test market is segmented on the basis of cancer type, site of collection and end use. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Cancer Type
- Bladder Cancer
- Breast Cancer
- Colon and Rectal Cancer
- Endometrial Cancer
- Kidney Cancer
- Leukemia
- Liver-Lung Cancer
- Melanoma
- Non-Hodgkin Lymphoma
- Pancreatic Cancer
- Prostate Cancer
- Thyroid Cancer
End-use
- Hospitals
- Diagnostic Laboratories
- Diagnostic Imaging Centers
- Cancer Research Institutes
Site of Collection
- Parotid Gland
- Submandibular/Sublingual Gland
- Minor Salivary Glands
Cancer Spit Test Market Regional Analysis/Insights
The global cancer spit test market is analysed and market size insights and trends are provided by country, cancer type, site of collection and end use as referenced above.
The countries covered in the global cancer spit test market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the global cancer spit test market due to the adoption of advanced technology along with rising number of laboratories in the region.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the adoption of simple lifestyle along with rising cases of breast cancer.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Cancer Spit Test Market Share Analysis
The global cancer spit test market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global cancer spit test market.
Some of the major players operating in the global cancer spit test market are:
- Thermo Fisher Scientific Inc. (U.S.)
- BD (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- bioMérieux (France)
- Merck KGaA (Germany)
- RayBiotech Life Inc. (U.S.)
- R&D Systems, Inc. (U.S.)
- AESKU.GROUP GmbH & Co. KG (Germany)
- Eurofins Scientific (Luxembourg)
- Biogenuix (India)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Abbott (U.S.)
- Danaher (U.S.)
- Sysmex Corporation (Japan)
- PerkinElmer Inc. (U.S.)
- Agilent Technologies Inc. (U.S.)
SKU-